Understand the peptide.
Know what to ask.
Explore peptides, hormone replacement therapy and IV therapy. Find source-linked information and named clinicians with dated license and service checks. No miracle claims or research-chemical storefronts.
A clear path to the information.
HRT for women
Evidence context, questions to ask and relevant directory checks.
Explore HRT for women →Start with the evidence notes.
Source-linked pages grounded in regulator and prescription-label material. Names are a way to find information, not recommendations.
5-Amino-1MQ (related non-peptide)
An experimental NNMT inhibitor, not a peptide.
Read the evidence notes →Abaloparatide
Tymlos has defined high-fracture-risk osteoporosis indications, not a general wellness indication.
Read the evidence notes →AICAR (related non-peptide)
A metabolic research compound often described as an exercise mimetic.
Read the evidence notes →AOD-9604
FDA identifies safety concerns or important evidence gaps. Research labeling is not permission for human use.
Read the evidence notes →ARA-290 / cibinetide
An erythropoietin-derived investigational peptide.
Read the evidence notes →Ascorbic acid IV (ASCOR)
ASCOR has a defined scurvy indication, not a general high-dose wellness indication.
Read the evidence notes →BPC-157
What FDA says about limited human safety information and compounding risks.
Read the evidence notes →Cagrilintide
A long-acting amylin analogue investigated for weight management.
Read the evidence notes →Cagrilintide + semaglutide (CagriSema)
A studied drug combination, not proof for a vendor-mixed blend.
Read the evidence notes →Cathelicidin LL-37
FDA identifies safety concerns or important evidence gaps. Research labeling is not permission for human use.
Read the evidence notes →CJC-1295
FDA reports limited clinical data and serious events associated with the compound.
Read the evidence notes →Compounded hormone preparations
Compounded hormone products are not FDA-approved products.
Read the evidence notes →Desmopressin
Desmoda oral solution has a central diabetes insipidus indication and important sodium and fluid-balance warnings.
Read the evidence notes →Dextrose + sodium chloride
Labeled carbohydrate/electrolyte IV solutions are not universal energy or hydration treatments.
Read the evidence notes →Dihexa acetate
FDA identifies safety concerns or important evidence gaps. Research labeling is not permission for human use.
Read the evidence notes →Dulaglutide
Trulicity is a prescription GLP-1 product with indication-specific diabetes context.
Read the evidence notes →Elamipretide / SS-31
Forzinity has accelerated approval for a narrow Barth-syndrome population, not general anti-aging use.
Read the evidence notes →Emideltide (DSIP)
FDA identifies safety concerns or important evidence gaps. Research labeling is not permission for human use.
Read the evidence notes →Epitalon
FDA identifies safety concerns or important evidence gaps. Research labeling is not permission for human use.
Read the evidence notes →Estradiol
Oral estradiol has product-specific menopause and other hormone indications.
Read the evidence notes →Estradiol + progesterone
A fixed oral combination for moderate-to-severe menopausal vasomotor symptoms in women with a uterus.
Read the evidence notes →Exenatide
A prescription GLP-1 product for adult type 2 diabetes, not a general wellness peptide.
Read the evidence notes →FOXO4-DRI
An experimental senolytic peptide; cell research is not human rejuvenation.
Read the evidence notes →GHK-Cu
FDA’s warning concerns injectable use. Keep product types and routes separate.
Read the evidence notes →Glutathione
FDA documents endotoxin concerns with ingredient quality in compounded injectable products.
Read the evidence notes →Growth hormone releasing peptide-2 (GHRP-2)
FDA identifies safety concerns or important evidence gaps. Research labeling is not permission for human use.
Read the evidence notes →Growth hormone releasing peptide-6 (GHRP-6)
FDA identifies safety concerns or important evidence gaps. Research labeling is not permission for human use.
Read the evidence notes →Hexarelin
A growth-hormone secretagogue with investigational endocrine context.
Read the evidence notes →Humanin
A mitochondrial-derived peptide investigated in age-related disease models.
Read the evidence notes →Ibutamoren mesylate
FDA identifies safety concerns or important evidence gaps. Research labeling is not permission for human use.
Read the evidence notes →IGF-1 LR3
A modified IGF-1 analogue, not the approved mecasermin product.
Read the evidence notes →Ipamorelin
FDA describes route-specific uncertainty and serious events reported in an intravenous study.
Read the evidence notes →Kisspeptin-10
FDA identifies safety concerns or important evidence gaps. Research labeling is not permission for human use.
Read the evidence notes →KPV
FDA has not identified human exposure data for KPV drug products.
Read the evidence notes →Lactated Ringer's solution
A labeled IV fluid for water/electrolytes or alkalinizing use, not a detoxification claim.
Read the evidence notes →Lanreotide
A somatostatin analog with acromegaly, GEP-NET and carcinoid-syndrome indications.
Read the evidence notes →Levocarnitine (L-carnitine)
A related non-peptide nutrient with defined prescription deficiency indications, not a fat-loss promise.
Read the evidence notes →Linaclotide
Linzess has indication- and age-specific constipation uses. Its label warns about dehydration and severe diarrhea.
Read the evidence notes →Liraglutide
Product-specific diabetes information. Do not merge every liraglutide brand or indication.
Read the evidence notes →Magnesium sulfate IV
A product-specific IV electrolyte/drug label, not a wellness-cocktail recommendation.
Read the evidence notes →Mazdutide
A dual glucagon / GLP-1 agonist; country-specific status matters.
Read the evidence notes →Mecasermin (IGF-1 prescription product)
Increlex treats defined pediatric growth failure; do not confuse it with IGF-1 LR3.
Read the evidence notes →Mechano growth factor pegylated (PEG-MGF)
FDA identifies safety concerns or important evidence gaps. Research labeling is not permission for human use.
Read the evidence notes →Melanotan II
FDA identifies safety concerns or important evidence gaps. Research labeling is not permission for human use.
Read the evidence notes →MOTS-c
FDA has not identified human exposure data for drug products containing MOTs-C.
Read the evidence notes →NAD+
Included because readers research it alongside peptides. FDA warns about food-grade ingredients in sterile injectable products.
Read the evidence notes →Octreotide
A somatostatin analog with specific acromegaly and tumor-symptom indications.
Read the evidence notes →Oxytocin
The injectable label describes obstetric uses and the need for trained observation, not wellness claims.
Read the evidence notes →Pramlintide
Symlin is an adjunct to mealtime insulin for specified diabetes patients, with a severe-hypoglycemia boxed warning.
Read the evidence notes →Progesterone
Oral progesterone capsules have defined endometrial-hyperplasia prevention and amenorrhea uses.
Read the evidence notes →PT-141 / Bremelanotide
The Vyleesi label has a narrow HSDD indication and important cardiovascular limits.
Read the evidence notes →Retatrutide
FDA says retatrutide is not a component of an approved drug and cannot be used in compounding under federal law.
Read the evidence notes →Selank
FDA identifies important gaps in safety information for selank acetate.
Read the evidence notes →Semaglutide
Wegovy injection and tablets have different labeled populations and indications.
Read the evidence notes →Semax
FDA says human safety information is absent or limited for proposed routes.
Read the evidence notes →Sermorelin
FDA’s 2013 Geref withdrawal determination is not approval of every compounded sermorelin claim.
Read the evidence notes →SLU-PP-332 (related non-peptide)
An experimental small-molecule ERR agonist, not a peptide.
Read the evidence notes →Sodium chloride IV solution
Product-specific saline information; concentrations and routes are not interchangeable.
Read the evidence notes →Survodutide
An investigational glucagon / GLP-1 receptor dual agonist.
Read the evidence notes →TB-500
FDA identifies TB-500 as a specific thymosin beta-4 fragment and notes missing human exposure data.
Read the evidence notes →Teduglutide
Gattex is a GLP-2 analog for short bowel syndrome with parenteral-support dependence, not a general gut-health treatment.
Read the evidence notes →Teriparatide
A parathyroid-hormone analog with high-fracture-risk osteoporosis indications.
Read the evidence notes →Tesamorelin
The EGRIFTA WR label describes a specific indication, not general weight-loss use.
Read the evidence notes →Testosterone cypionate
Depo-Testosterone has defined testosterone-deficiency indications, not an established age-related wellness indication.
Read the evidence notes →Thiamine injection (vitamin B1)
A labeled injectable vitamin product for deficiency-related clinical care, not a blanket energy claim.
Read the evidence notes →Thymosin-alpha 1 (Ta1)
FDA identifies safety concerns or important evidence gaps. Research labeling is not permission for human use.
Read the evidence notes →Tirzepatide
Zepbound has specific weight-management and sleep-apnea indications. Compounded versions are separate.
Read the evidence notes →Information is not an endorsement.
No dosing guides, treatment promises or made-up clinic rankings. Every information page links its sources and names what they cannot establish.
Read our publishing standards →